SEC Form S-8 filed by Zentalis Pharmaceuticals Inc.
$ZNTL
Biotechnology: Pharmaceutical Preparations
Health Care
As filed with the Securities and Exchange Commission on May 14, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Zentalis Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
| Delaware | 82-3607803 | ||||
(State or other jurisdiction of Incorporation or organization) | (I.R.S. Employer Identification No.) | ||||
10275 Science Center Dr., Suite 200
San Diego, California 92121
(858) 263-4333
(Address of principal executive offices) (Zip code)
Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan
Zentalis Pharmaceuticals, Inc. 2020 Incentive Award Plan
(Full titles of the plans)
Andrea Paul
Chief Legal Officer and Corporate Secretary
Zentalis Pharmaceuticals, Inc.
10275 Science Center Dr., Suite 200
San Diego, California 92121
(858) 263-4333
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
With copies to:
Nathan Ajiashvili
Jenna Cooper
Salvatore Vanchieri
Latham & Watkins LLP
1271 Avenue of the Americas
New York, NY 10020
(212) 906-1200
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||||||||||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||||||||||
| Emerging growth company | ☐ | |||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement registers the offer and sale of (i) 5,500,000 shares of common stock of Zentalis Pharmaceuticals, Inc. (the “Company”) for issuance under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (as amended and/or restated from time to time, the “Inducement Plan”), and (ii) an additional 1,200,000 shares of common stock of the Company for issuance under the Zentalis Pharmaceuticals, Inc. 2020 Incentive Award Plan (as amended and/or restated from time to time, the “2020 Plan”) pursuant to its terms.
INCORPORATION BY REFERENCE OF CONTENTS OF
REGISTRATION STATEMENTS ON FORM S-8
REGISTRATION STATEMENTS ON FORM S-8
The contents of the Registration Statements on Form S-8 (File Nos. 333-237593, 333-266702, and 333-277550), including any amendments thereto, filed with the Securities and Exchange Commission, relating to the 2020 Plan and the Inducement Plan, are incorporated herein by reference.
Item 8. Exhibits
| Incorporated by Reference | ||||||||||||||||||||||||||||||||||||||
Exhibit Number | Description | Form | Exhibit | Date Filed | File Number | Filed Herewith | ||||||||||||||||||||||||||||||||
4.1 | S-8 | 4.1 | 04/07/2020 | 333-237593 | ||||||||||||||||||||||||||||||||||
| 4.2 | 8-K | 3.1 | 06/16/2023 | 001-39263 | ||||||||||||||||||||||||||||||||||
3 | 8-K | 3.1 | 02/15/2024 | 001-39263 | ||||||||||||||||||||||||||||||||||
4 | S-1 | 4.2 | 03/06/2020 | 333-236959 | ||||||||||||||||||||||||||||||||||
| 5.1 | X | |||||||||||||||||||||||||||||||||||||
| 10.1 | 10-K | 10.5.1 | 03/26/2025 | 001-39263 | ||||||||||||||||||||||||||||||||||
10.2 | 8-K | 10.2 | 07/22/2022 | 001-39263 | ||||||||||||||||||||||||||||||||||
10.3 | 8-K | 10.3 | 07/22/2022 | 001-39263 | ||||||||||||||||||||||||||||||||||
10.4 | S-1/A | 10.2 | 03/30/2020 | 333-236959 | ||||||||||||||||||||||||||||||||||
10.5 | 10-Q | 10.3 | 05/17/2021 | 001-39263 | ||||||||||||||||||||||||||||||||||
| 23.1 | X | |||||||||||||||||||||||||||||||||||||
| 23.2 | X | |||||||||||||||||||||||||||||||||||||
| 24.1 | X | |||||||||||||||||||||||||||||||||||||
| 107.1 | X | |||||||||||||||||||||||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, California, on May 14, 2025.
| ZENTALIS PHARMACEUTICALS, INC. | |||||
| By: | /s/ Julie Eastland | ||||
Julie Eastland | |||||
| President and Chief Executive Officer | |||||
POWER OF ATTORNEY
Each person whose signature appears below hereby constitutes and appoints Julie Eastland or Vincent Vultaggio, or each of them singly, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date | ||||||||||||
| /s/ Julie Eastland | President and Chief Executive Officer | May 14, 2025 | ||||||||||||
| Julie Eastland | (principal executive officer) | |||||||||||||
| /s/ Vincent A. Vultaggio | Senior Vice President, Finance and Principal Accounting Officer | May 14, 2025 | ||||||||||||
| Vincent A. Vultaggio | (principal financial and accounting officer) | |||||||||||||
| /s/ Scott Myers | Chairperson | May 14, 2025 | ||||||||||||
| Scott Myers | ||||||||||||||
| /s/ David Johnson | Director | May 14, 2025 | ||||||||||||
| David Johnson | ||||||||||||||
| /s/ Enoch Kariuki | Director | May 14, 2025 | ||||||||||||
| Enoch Kariuki | ||||||||||||||
| /s/ Jan Skvarka | Director | May 14, 2025 | ||||||||||||
| Jan Skvarka | ||||||||||||||
| /s/ Karan Takhar | Director | May 14, 2025 | ||||||||||||
| Karan Takhar | ||||||||||||||
| /s/ Luke Walker, M.D. | Director | May 14, 2025 | ||||||||||||
| Luke Walker, M.D. | ||||||||||||||